The Supreme Court of India dismissed an appeal filed by Progfin Private Limited against the National Company Law Appellate Tribunal (NCLAT) order, effectively ending the legal challenge seeking to initiate a corporate insolvency resolution process (CIRP) against Ganesh Benzoplast . The apex court delivered its verdict on August 18, 2026, stating that the appellant did not have sufficient grounds to contest the NCLAT’s decision.

This development marks the final judicial rejection of Progfin’s attempt to push Ganesh Benzoplast into insolvency proceedings under the Insolvency and Bankruptcy Code, 2016. The company disclosed the outcome in a filing with stock exchanges on August 20, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Litigation Background

The dispute originated from alleged defaults in repayment of credit facilities extended to GBL Chemical Limited, a wholly owned subsidiary of Ganesh Benzoplast. Progfin claimed these facilities were backed by a corporate guarantee purportedly issued by the parent company.

Progfin initially filed a Section 7 petition before the National Company Law Tribunal (NCLT), Mumbai Bench, seeking to initiate CIRP against Ganesh Benzoplast. The NCLT dismissed this petition on September 1, 2025.

Following the NCLT’s rejection, Progfin appealed to the NCLAT. The appellate tribunal upheld the NCLT’s decision and dismissed the appeal on June 30, 2026. Progfin subsequently approached the Supreme Court, which has now closed the matter by dismissing the final appeal.

Financial Implications

Ganesh Benzoplast stated in its regulatory filing that there are no expected financial implications, such as compensation or penalties, arising from this litigation. The company also confirmed that there is no quantum of claims pending against it in relation to this specific dispute.

What the Numbers Show

The complete dismissal of the insolvency petition at all three levels of adjudication—NCLT, NCLAT, and the Supreme Court—indicates a consistent judicial finding that the grounds for initiating CIRP were not substantiated. With no financial penalties or outstanding claims attached to this specific legal battle, the resolution removes a potential overhang on the company’s balance sheet regarding this particular creditor dispute.

Ganesh Benzoplast disclosed on August 19, 2026, that Ravi Pilani intends to acquire 28,56,810 equity shares of the company through a gift transfer from promoters Rishi Pilani and Poonam Pilani. The proposed transaction falls under Regulation 10(1)(a)(i) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which exempts off-market transfers between promoters and their immediate relatives from making an open offer.

The acquisition will be completed on or before August 27, 2026. As this is an inter-se transfer among immediate relatives, there is no change in the aggregate holding of the promoter and promoter group. The total stake held by the promoter group remains unchanged before and after the transaction.

Transaction Details

The shares are being transferred without consideration. The breakdown of the proposed acquisition is as follows:

Ravi Pilani, who is not currently a promoter of the company but is an immediate relative (brother) of Chairman and Managing Director Rishi Pilani, will hold 3.97% of the total paid-up share capital post-transaction. Prior to this transfer, his holding was zero.

Regulatory Compliance

The company filed the intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ravi Pilani submitted the requisite disclosure under Regulation 10(5) of the SEBI (SAST) Regulations, 2011, confirming compliance with all conditions for exemption. The acquirer declared that all applicable requirements in Chapter V of the Takeover Regulations have been met.